TORONTO, Oct. 19, 2020 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a medical
cannabis leader with core operations in Latin America and Europe announced the appointment, effective
October 16, of Joel Friedman as CFO following the resignation
of Wendy Kaufman, the Company's CFO
since July, 2019. Ms. Kaufman is departing to return to the
mining industry where she has spent the greater part of her
executive career.
Since joining Khiron as Director of Finance and Treasury in
December 2019, Mr. Friedman has
worked closely with Ms. Kaufman and, in the view of the Audit
Committee, was a natural successor to the role of CFO. Mr.
Friedman, a Chartered Professional Accountant, began his career at
Deloitte. He brings over 10 years of international financial
experience, including in the cannabis and mining industries, having
previously served as Vice President, Finance at CannTrust Inc.,
Director of Finance at Primero Mining Corp., in addition to
progressively senior finance roles at Banro Corp. and Iamgold
Corporation.
"On behalf of our management team and Board of Directors, I
congratulate Joel on his promotion to the role of CFO. Having
worked closely with Joel for almost a year, we have full confidence
in Joel's experience and financial leadership to assume this
important role at Khiron as we continue to grow our operations and
brands in Latin America and
internationally," commented Deborah
Rosati, Chair of Khiron's Audit Committee.
Alvaro Torres, Khiron's CEO
stated, "On behalf of the Board of Directors and the entire Khiron
team, I would like to thank Wendy for her contributions as CFO
during Khiron's critical phases of growth and commercialization,
and for her excellent stewardship during the global challenges that
the Company has faced over the past six months as a result of the
COVID-19 pandemic. We also want to recognize Wendy for her
leadership and mentorship, ensuring a smooth transition and
continuity in the role of CFO to her successor, Joel. We wish Wendy
the very best in her new role."
About Khiron Life Sciences Corp.
Khiron is a medical and CPG cannabis company with core
operations in Latin America, and
operational activity in Europe and
North America. Khiron is the leading cannabis company in
Colombia and the first company
licensed in Colombia for the
cultivation, production, domestic distribution and sales, and
international export of both low and high THC medical cannabis
products. The Company has filled medical cannabis prescriptions in
Peru and has a presence in
Mexico, Uruguay, UK, Spain and also in Germany, where it is positioned to begin sales
of medical cannabis.
Leveraging its first-mover advantage and patient-oriented
approach, Khiron combines global scientific expertise, product
innovation, agricultural infrastructure, wholly-owned medical
clinics, and online doctor education programs to drive prescription
and brand loyalty to address priority medical conditions. Its
Wellbeing unit launched the first branded CBD skincare brand in
Colombia, with KuidaTM
now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is
led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-appoints-joel-friedman-to-succeed-wendy-kaufman-as-chief-financial-officer-301154712.html
SOURCE Khiron Life Sciences Corp.